NCT07033481View on ClinicalTrials.gov

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
DRUG

Neflamapimod

Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules

DRUG

Placebo

Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Trial Locations (3)

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

43221

RECRUITING

The Ohio State University, Columbus

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

EIP Pharma Inc

Collaborators (1)

CervoMed, Inc
All Listed Sponsors
collaborator

CervoMed, Inc

UNKNOWN

lead

EIP Pharma Inc

INDUSTRY

NCT07033481 - Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Biotech Hunter | Biotech Hunter